Prolactin Inhibitors Market is anticipated to exhibit a CAGR of 3.5% from 2023 to 2031
Newark, New Castle, USA, May 24, 2023 (GLOBE NEWSWIRE) -- The market analysis of the global *prolactin inhibitors market* was conducted by Growth Plus Reports in 2022. The market is expected to hit a revenue *CAGR of 3.5% by 2031*.
Analysis of the global market for prolactin inhibitors indicates that the revenue share is likely to increase significantly. Prolactin inhibitors are the main treatment for hyperprolactinemia (high prolactin levels). Dopamine D2 receptor antagonists like bromocriptine and cabergoline, which have the potential to drastically lower pituitary prolactin production and circulating prolactin levels, are the most often used prolactin inhibitors.
*Key Takeaways: *
· The increasing number of patients with high prolactin levels is driving the market revenue share.
· The growing efforts in research and development to offer effective and long-lasting therapy options are driving the market demand.
· A rapidly expanding patient population and rising medicine demand would affect a market's ability to expand internationally.
*Get a Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/prolactin-inhibitors-market/9046*
* Prolactin Inhibitors Market Scope*
*Report Attribute* *Details*
CAGR 3.5%
Base Year for Estimation 2022
Forecast Period 2023 to 2031
Historical Year 2021
Segments Covered Drug, Indication, and Region
Regional Scope North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
*Competitive Landscape*
A list of the companies operating in the global market for prolactin inhibitors includes:
· Midas Pharma
· Pfizer, Inc.
· Alembic Pharmaceuticals Ltd.
*Market Drivers and Restraints: *
The global prolactin inhibitors market revenue is driven by the cases of hyperprolactinemia, increasing R&D activities, and rising government investments in potential drug development. The market revenue growth is also impacted by the degree to which patients and healthcare providers are aware of the illness' signs and symptoms, which include irregular menstrual periods, infertility, and galactorrhea (milky nipple discharge).
*Market Segmentation: *
· Based on the drug, the global prolactin inhibitors market is segmented into bromocriptine, cabergoline, and others.
· Based on indication, the global prolactin inhibitors market is segmented into hyperprolactinemia, acromegaly, type 2 diabetes, and others.
*Segmentation By Indication*
Based on the indication, the type 2 diabetes segment dominates the global prolactin inhibitors market with the largest revenue share. One prolactin inhibitor, bromocriptine, has shown promise in preclinical and early clinical research. It has been seen to enhance insulin signaling and enhance glycemic control in people with type 2 diabetes. This increases the overall segment's revenue growth.
*Regional Growth Dynamics*
Based on the region, North America, with the largest revenue share, dominates the global prolactin inhibitors market. This sizable share of revenue is due to the revenue growth of type 2 diabetes in the region. A detailed study and analysis are provided in our report. Increased demand for the appropriate therapies may result from efforts for the awareness of healthcare professionals for the disease.
*Request for Customization – https://www.growthplusreports.com/inquiry/customization/prolactin-inhibitors-market/9046*
*Report Coverage *
Growth Plus Reports carried out extensive market research on the prolactin inhibitors market globally. We examined the fundamental market characteristics, significant investment opportunities, regional growth patterns, ten-year revenue estimates, competing market players, and mergers and acquisitions.
*Table of Content*
1. *INTRODUCTION*
1. Market Ecosystem
2. Timeline Under Consideration
1. Historical Years – 2021
2. Base Year – 2022
3. Forecast Years – 2023 to 2031
3. Currency Used in the Report
2. *RESEARCH METHODOLOGY *
1. Research Approach
2. Data Collection Methodology
3. Data Sources
1. Secondary Sources
2. Primary Sources
4. Market Estimation Approach
1. Bottom Up
2. Top Down
5. Market Forecasting Model
6. Limitations and Assumptions
3. *PREMIUM INSIGHTS*
1. Current Market Trends (COVID-19 Perspective)
2. Key Players & Competitive Positioning (2022)
3. Regulatory Landscape
4. *MARKET DYNAMICS*
1. Drivers
2. Restraints/Challenges
3. Opportunities
5. *GLOBAL PROLACTIN INHIBITORS MARKET - ANALYSIS & FORECAST, BY DRUG*
1. Bromocriptine
2. Cabergoline
3. Others
6. *GLOBAL PROLACTIN INHIBITORS MARKET - ANALYSIS & FORECAST, BY INDICATION*
1. Hyperprolactinemia
2. Acromegaly
3. Type 2 Diabetes
4. Others
*PROLACTIN INHIBITORS MARKET TOC*
*Buy this Premium Research Report:* *https://www.growthplusreports.com/checkout-9046*
*VALUE PROPOSITIONS RELATED TO THE REPORT*:
· Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
· Comprehensive quantitative and qualitative insights at segment and sub-segment level
· Covid 19 impact trends and perspective
· Granular insights at global/regional/country level
· Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
· Blanket coverage on competitive landscape
· Winning imperatives
· Exhaustive coverage on 'Strategic Developments' registered by leading players of the market.
*CUSTOMIZATION OPTIONS*:
· Distributor Landscape Assessment
· Pricing Intelligence
· Customer Base Assessment
· Investment & Initiatives Analysis
· 'Business Profile' of Key Players
*Schedule a call with our analyst: **https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction*
*Visit our report store at - **https://www.growthplusreports.com/report-store*
*Browse more latest healthcare reports:*
*Opioid Induced Constipation Treatment Market* by Drug Class (Laxatives, Peripherally Acting μ-opioid Receptor Antagonists), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
*Lithotripsy Devices Market* by Type (Extracorporeal Shock Wave Lithotripsy Devices, Intracorporeal Lithotripsy Devices), Application (Kidney Stones, Ureteral Stones), End User (Hospitals, Ambulatory Surgical Centers) – Global Outlook & Forecast 2023-2031
*Veterinary Auto-Immune Disease Diagnostics Market* by Test Type (DNA Amplification Test, Biopsy Test), Indication (Canine Lupus, Pemphigus Disease), End User (Veterinary Hospital, Veterinary Clinics) – Global Outlook & Forecast 2023-2031
*Cranial and Facial Implants Market* by Type (Cranial, Facial), Material (Polymethyl Methacrylate, Porous Polyethylene) – Global Outlook & Forecast 2023-2031
*Intervertebral Implants Market* by Тype (Lumbar, Cervical), Material (Titanium, PEEK) – Global Outlook & Forecast 2023-2031
*Unleashing the Power of Innovation in Med Tech* *https://growthplusmedtechroundup.com/*
*About Us:*
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
CONTACT: Manan Sethi
Director, Market Insights
Email: sales@growthplusreports.com
256 Chapman Road
STE 105-4, Newark,
New Castle - 19702, USA
Phone no: +1 888 550 5009
Web: https://www.growthplusreports.com/